
|Videos|July 12, 2016
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Overview of the Lume 1 and 2 Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, Mayo Clinic in Rochester, Minnesota, discusses the Lume 1 and 2 trials as well as new treatment options for metastatic colorectal cancer.
Advertisement
Articles in this issue
over 9 years ago
Role of DPR in Colorectal Cancerover 9 years ago
Impact of HER2 Amplification in Colorectal Cancerover 9 years ago
Novel Immunotherapy Combinations on Horizon for mCRCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5










































